Renaissance Technologies LLC purchased a new position in Beam Therapeutics Inc. (NASDAQ:BEAM - Free Report) in the 4th quarter, according to the company in its most recent disclosure with the SEC. The fund purchased 22,907 shares of the company's stock, valued at approximately $568,000.
Several other institutional investors also recently bought and sold shares of the company. Wealthfront Advisers LLC purchased a new position in shares of Beam Therapeutics in the 4th quarter worth $41,000. KBC Group NV raised its position in Beam Therapeutics by 103.2% in the fourth quarter. KBC Group NV now owns 4,143 shares of the company's stock worth $103,000 after acquiring an additional 2,104 shares during the period. Blue Trust Inc. grew its position in shares of Beam Therapeutics by 36.3% during the 4th quarter. Blue Trust Inc. now owns 4,274 shares of the company's stock valued at $105,000 after acquiring an additional 1,139 shares during the period. GAMMA Investing LLC lifted its position in Beam Therapeutics by 23.9% during the fourth quarter. GAMMA Investing LLC now owns 5,722 shares of the company's stock valued at $142,000 after purchasing an additional 1,102 shares in the last quarter. Finally, Atria Investments Inc lifted its position in shares of Beam Therapeutics by 17.1% during the 4th quarter. Atria Investments Inc now owns 9,562 shares of the company's stock valued at $237,000 after buying an additional 1,395 shares in the last quarter. 99.68% of the stock is owned by hedge funds and other institutional investors.
Beam Therapeutics Stock Performance
Shares of NASDAQ:BEAM traded up $0.55 on Friday, hitting $17.80. 1,156,476 shares of the company's stock were exchanged, compared to its average volume of 1,426,838. The company has a market capitalization of $1.79 billion, a PE ratio of -10.11 and a beta of 2.35. Beam Therapeutics Inc. has a 1-year low of $13.53 and a 1-year high of $35.25. The firm's 50-day moving average is $20.25 and its 200 day moving average is $24.36.
Beam Therapeutics (NASDAQ:BEAM - Get Free Report) last announced its quarterly earnings data on Tuesday, May 6th. The company reported ($1.24) EPS for the quarter, missing the consensus estimate of ($1.11) by ($0.13). Beam Therapeutics had a negative net margin of 41.07% and a negative return on equity of 16.22%. The company had revenue of $7.47 million during the quarter, compared to analyst estimates of $14.69 million. During the same quarter last year, the business earned ($1.21) EPS. The firm's revenue for the quarter was up 1.4% on a year-over-year basis. On average, analysts anticipate that Beam Therapeutics Inc. will post -4.57 EPS for the current fiscal year.
Insider Activity
In related news, CEO John M. Evans sold 30,663 shares of the business's stock in a transaction dated Tuesday, April 1st. The stock was sold at an average price of $18.35, for a total value of $562,666.05. Following the transaction, the chief executive officer now owns 986,249 shares in the company, valued at approximately $18,097,669.15. The trade was a 3.02 % decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the SEC, which can be accessed through this link. Also, President Giuseppe Ciaramella sold 7,434 shares of the stock in a transaction dated Tuesday, April 1st. The stock was sold at an average price of $18.35, for a total transaction of $136,413.90. Following the transaction, the president now directly owns 190,216 shares in the company, valued at $3,490,463.60. The trade was a 3.76 % decrease in their position. The disclosure for this sale can be found here. Insiders sold a total of 43,771 shares of company stock valued at $803,198 over the last 90 days. Insiders own 4.20% of the company's stock.
Analyst Ratings Changes
BEAM has been the topic of a number of research analyst reports. Bank of America upgraded Beam Therapeutics from a "neutral" rating to a "buy" rating and set a $42.00 target price on the stock in a research report on Friday, March 28th. Guggenheim decreased their price objective on shares of Beam Therapeutics from $78.00 to $55.00 and set a "buy" rating for the company in a research report on Wednesday. HC Wainwright reaffirmed a "buy" rating and set a $80.00 price target on shares of Beam Therapeutics in a research report on Monday, April 7th. Royal Bank of Canada boosted their price objective on Beam Therapeutics from $24.00 to $26.00 and gave the company a "sector perform" rating in a report on Wednesday, February 26th. Finally, Cantor Fitzgerald restated an "overweight" rating on shares of Beam Therapeutics in a research report on Wednesday, March 12th. Two research analysts have rated the stock with a hold rating, eleven have given a buy rating and two have assigned a strong buy rating to the company. Based on data from MarketBeat.com, the company currently has a consensus rating of "Buy" and a consensus target price of $48.75.
Get Our Latest Report on BEAM
About Beam Therapeutics
(
Free Report)
Beam Therapeutics Inc, a biotechnology company, engages in the development of precision genetic medicines for patients suffering from serious diseases in the United States. It develops BEAM-101 for the treatment of sickle cell disease or beta-thalassemia; and BEAM-302, a liver-targeting LNP formulation to treat severe alpha-1 antitrypsin deficiency; BEAM-201, an anti-CD7 CAR-T product candidate, which is in Phase 1/2 clinical trials for the treatment of refractory T-cell acute lymphoblastic leukemia/T cell lymphoblastic lymphoma; and BEAM-301, a liver-targeting LNP formulation for the treatment of glycogen storage disease 1a.
Read More

Before you consider Beam Therapeutics, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Beam Therapeutics wasn't on the list.
While Beam Therapeutics currently has a Buy rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
MarketBeat's analysts have just released their top five short plays for June 2025. Learn which stocks have the most short interest and how to trade them. Enter your email address to see which companies made the list.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.